✦ LIBER ✦

SH2 and SH3 domains: Potential targets for anti-cancer drug design

✍ Scribed by Thomas E. Smithgall

Book ID: 113409944
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 990 KB
Volume: 34
Category: Article
ISSN: 1056-8719
DOI: 10.1016/1056-8719(95)00082-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

SH2 domain binding to phosphopeptide lig

SH2 domain binding to phosphopeptide ligands: potential for drug targeting

✍ Kasembeli, Moses, M. 📂 Article 📅 2009 🏛 Frontiers in BioScience 🌐 English ⚖ 284 KB

SH3 domains and drug design: Ligands, st

SH3 domains and drug design: Ligands, structure, and biological function

✍ D. C. Dalgarno; M. C. Botfield; R. J. Rickles 📂 Article 📅 1997 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 567 KB

The ligand binding preferences, structural features, and biological function of SH3 (Src homology 3) domains are discussed. SH3 domains bind ''core'' Pro-rich peptide ligands (7-9 amino acids in length) in a polyproline II helical conformation in a highly conserved aromatic rich patch on the protein

Implications of SH3 domain structure and

Implications of SH3 domain structure and dynamics for protein regulation and drug design

✍ William H. Gmeiner; David A. Horita 📂 Article 📅 2001 🏛 Springer-Verlag 🌐 English ⚖ 255 KB

Prenyl-binding domains: potential target

Prenyl-binding domains: potential targets for Ras inhibitors and anti-cancer drugs

✍ Yoel Kloog; Adrienne D Cox 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 178 KB

G-quadruplex DNA: a potential target for

G-quadruplex DNA: a potential target for anti-cancer drug design

✍ Haiyong Han; Laurence H Hurley 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 238 KB

Design and characterization of non-Phosp

Design and characterization of non-Phosphopeptide inhibitors for Src family SH2 domains

✍ See-Hyoung Park; Jonghwa Won; Keun-Hyeung Lee 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 117 KB